A recent systematic review and meta-analysis demonstrated the good detection rate of PET/CT with PSMA-targeted agents radiolabeled with 18F (including 18F-PSMA-1007) in the setting of PCa restaging after primary treatment (as surgery or radiation treatment) [20]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.